Regulus (RGLS) Has a New Rating from H.C. Wainwright

By Ryan Adsit

Regulus (RGLSResearch Report) received a Buy rating and a $2 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed last Monday at $0.60, close to its 52-week low of $0.50.

Selvaraju commented:

“We have assessed Regulus Therapeutics using a discounted cash flow (DCF)-based approach, which ascribes value solely to the RGLS4326 program and the development-related milestone payments slated to be paid by Sanofi contingent upon continued progress with RG-012. Our assumptions include a 15% probability of regulatory approval for 20% probability of continued clinical advancement for RG-012. We also utilize a 15% discount rate, 0.5% terminal growth rate and 30% effective tax rate.”

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.1% and a 29.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Regulus has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

See today’s analyst top recommended stocks >>

Based on Regulus’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.02 million. In comparison, last year the company had a GAAP net loss of $13.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.